-
Janssen Sues Distributors Over Counterfeit Antiretroviral Therapies in the US
•
Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, filed a lawsuit last week against pharmaceutical distributors selling counterfeit versions of its antiretroviral therapies to three pharmacies in the United States. The move comes after the company became aware of the situation in 2020. The products primarily affected include the complete…
-
Columbia University Study Weighs Cost-Effectiveness of Weight-Loss Treatments for Adolescents
•
Researchers at US Columbia University have published the results of a study estimating the cost-effectiveness of Novo Nordisk’s (NYSE: NVO) injections Wegovy (semaglutide) and Saxenda (liraglutide), as well as Vivus’s (NASDAQ: VVUS) pill Qsymia (phentermine + topiramate) for weight-loss interventions in adolescents. The study utilized a simulated cohort of 100,000…
-
Shanghai Pharmaceuticals Executives Under Investigation for Serious Disciplinary Violations
•
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has disclosed that several former executives are suspected of serious violations of discipline and law. Pan Deqing, the company’s former vice-president, Chen Binhua, former general manager of subsidiary SPH NO.1 Biochemical & Pharmaceutical Co., Ltd, and Li Ping, former…
-
BDgene Technology Announces Clinical Milestone for CRISPR-Cas9 Gene Therapy in HSK
•
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced the conclusion of three clinical research treatments using its HELP technology, based on the CRISPR-Cas9 gene editing tool, for herpes simplex keratitis (HSK). Preliminary positive results have been published in the journal Molecular Therapy, in an article titled “In Vivo…
-
Sanofi Announces Management Restructuring with New Leadership Roles in China
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced a significant restructuring of its management structure in China, introducing three new global management positions and two new leadership teams to enhance operations and strategic alignment within the region. New Global Management Posts in ChinaThe newly created positions include the role of…
-
ImmuneOnco Biopharmaceuticals Begins Trading on HKEX with Successful IPO
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) marked its debut on the Hong Kong Stock Exchange this morning, with a positive start as its share price surpassed the issuance price of RMB 18.6 per share in early trading. The initial public offering (IPO) is anticipated to raise over HKD 300…
-
Sihuan Pharmaceutical’s Birociclib NDA Accepted for Review by China’s NMPA
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for birociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, for review. The drug is intended for the treatment of HR+/HER2- advanced breast cancer in patients who have…
-
Bloomage Biotech Terminates Joint Venture with Medytox Inc. for Botulinum Toxin Development
•
China-based Bloomage Biotech (SHA: 688363) has revealed that a termination agreement has been signed with South Korea-headquartered Medytox Inc., and its subsidiary Bloomage Cayman, along with the joint venture (JV) Medybloom Ltd. This termination signifies the cancellation of two key agreements. Cancellation of Joint Venture and Sole Agency AgreementsThe first…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
